Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic ModelJulia Scarisbrick, Henry K. Wong, H. Miles Prince et al.|Journal of Clinical Oncology|2015Cited by 419
Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort studyMarie Kostine, Thierry Schaeverbeke, L. Rouxel et al.|Annals of the Rheumatic Diseases|2017Cited by 302
The PROCLIPI international registry of early‐stage mycosis fungoides identifies substantial diagnostic delay in most patientsJulia Scarisbrick, Andrew Bates, Pablo L. Ortiz‐Romero et al.|British Journal of Dermatology|2018Cited by 235
Trough dabrafenib plasma concentrations can predict occurrence of adverse events requiring dose reduction in metastatic melanomaMarine Rousset, Mathiéu Molimard, Caroline Dutriaux et al.|Clinica Chimica Acta|2017Cited by 36
An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patientsMarine Rousset, Mathiéu Molimard, Karine Titier et al.|Clinica Chimica Acta|2017Cited by 33